OncoLize pitching at RESI, PODD and Bio Europe

12th September 2024

Pharma-tech OncoLize is pitching its recent successes in pre-clinical pancreatic cancer treatment at RESI (4-6 September), PODD (28-29 October) and Bio-Europe (4-6 November) to complete its seed round with €1.5 million in order to finalize its safety and tox studies, scale-up to cGMP grade and preprare for Clinical Trial Application. The round is supported by current shareholders in anticipation of a Series A of €10+ million to start Clinical Trials in 2026 and to expand the portfolio into other tumor diseases.